- Home
- ROMA vs PLX Comparison
ROMA vs PLX Comparison
Compare ROMA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- PLX
- Stock Information
- Founded
- ROMA 2018
- PLX 1993
- Country
- ROMA Hong Kong
- PLX United States
- Employees
- ROMA N/A
- PLX N/A
- Industry
- ROMA Savings Institutions
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROMA Finance
- PLX Health Care
- Exchange
- ROMA Nasdaq
- PLX Nasdaq
- Market Cap
- ROMA 150.7M
- PLX 164.2M
- IPO Year
- ROMA 2024
- PLX 1998
- Fundamental
- Price
- ROMA $3.16
- PLX $2.13
- Analyst Decision
- ROMA
- PLX Strong Buy
- Analyst Count
- ROMA 0
- PLX 1
- Target Price
- ROMA N/A
- PLX $15.00
- AVG Volume (30 Days)
- ROMA 72.8K
- PLX 756.6K
- Earning Date
- ROMA 09-25-2025
- PLX 11-13-2025
- Dividend Yield
- ROMA N/A
- PLX N/A
- EPS Growth
- ROMA N/A
- PLX N/A
- EPS
- ROMA N/A
- PLX 0.08
- Revenue
- ROMA $1,568,345.00
- PLX $61,948,000.00
- Revenue This Year
- ROMA N/A
- PLX $14.53
- Revenue Next Year
- ROMA N/A
- PLX $75.77
- P/E Ratio
- ROMA N/A
- PLX $26.60
- Revenue Growth
- ROMA 23.21
- PLX 62.79
- 52 Week Low
- ROMA $0.58
- PLX $0.99
- 52 Week High
- ROMA $4.66
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ROMA 54.91
- PLX 70.97
- Support Level
- ROMA $2.50
- PLX $1.52
- Resistance Level
- ROMA $3.37
- PLX $2.12
- Average True Range (ATR)
- ROMA 0.30
- PLX 0.10
- MACD
- ROMA -0.00
- PLX 0.02
- Stochastic Oscillator
- ROMA 73.41
- PLX 92.86
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.